EMA Regulatory Readiness Moves Upstream in Drug Development
EMA Executive Director Emer Cooke and EISMEA Director Momchil Sabev signed a letter of intent that formalizes their cooperation. The organizations have worked together since 2021. However, the new rolling program turns that relationship into specific activities for 2026 and 2027.
EMA and EISMEA will provide guidance, training, outreach, and stakeholder engagement. They will also continue horizon scanning and regulatory-readiness work for new health technologies. As a result, EIC-funded innovators can consider regulatory expectations while they still have room to shape development plans.
Small Biotechs Face Higher CMC Risk Without Early EMA Support
The program focuses on SMEs, start-ups, spin-offs, universities, and research organizations. Many lead high-risk scientific projects but lack established quality, CMC, or regulatory teams during early development.
Therefore, earlier access to regulatory expertise can improve planning before companies commit to pivotal studies, manufacturing platforms, or scale-up routes. The partnership does not announce a new legal requirement. Instead, it shows why innovators should treat regulatory strategy as an early development function.
Late CMC Planning Can Trigger Costly Rework Before Scale-Up
Scientific promise alone cannot move a medicine toward authorization. Developers must also define how they will manufacture, test, control, and document the product. Moreover, early choices shape later CMC packages, control strategies, analytical plans, and manufacturing readiness.
When companies delay these discussions, they may need to revise processes after key decisions. Smaller teams face greater exposure because they may build technical plans without enough regulatory input. Consequently, early engagement can align product development with future European expectations before changes become harder.
Complex Therapies Raise the Stakes for EMA Regulatory Readiness
Early planning becomes more important for cell and gene therapies, personalized medicines, medtech products, and technologies that combine drugs with digital or artificial intelligence components. These products connect scientific, manufacturing, data, and regulatory questions.
Therefore, teams need more than a strong clinical concept. They also need a clear development pathway, reliable evidence, appropriate controls, and a quality structure that matures with the product. EMA and EISMEA aim to help innovators understand these challenges before later and more expensive development stages.
Quality Systems Become Critical Long Before Submission
The cooperation has already increased awareness of EMA support tools. An EMA-EIC survey found that three-quarters of participating innovators gained greater awareness after joint training, while 95% said they would use the tools again. However, awareness creates value only when companies translate regulatory knowledge into development decisions and daily quality practices.
Zamann Pharma’s Quality Management Systemservice helps pharmaceutical teams build and strengthen practical quality systems for compliant operations. Companies preparing for scale-up or closer regulatory engagement can explore this support to identify quality gaps before they become harder to correct.
Source: Pharmtech.Com